FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308839704> ?p ?o ?g. }

• W4308839704 abstract "Abstract Background Dimethyl fumarate (DMF) and ocrelizumab are two effective immunomodulators for multiple sclerosis (MS) with distinct mechanisms of action. Identifying overlapping therapeutic effects between both agents may elucidate common pathways in preventing disease activity. Objectives In this study we analyzed cytokine and immune-profiling data to evaluate the similarities and differences between the two disease-modifying therapies for MS. Methods : Plasma and PBMCs from MS patients were collected at baseline, 3 months and 6 months after treatment with DMF (n=16) and ocrelizumab (n=13). Immunophenotyping was performed with mass cytometry (CyTOF) and analyzed with gating based on cell surface markers. Cytokine analysis from plasma was performed with Olink assays and analyzed with linear mixed effects models. Results DMF reduced both effector T and memory B cell populations while increasing CD56 bright natural killer (NK) cells. Ocrelizumab exerted its main immunomodulatory effect by reducing the frequency of all B cells and increasing frequency of NK cells. At 6 months, naive B-cells began to reconstitute; however, memory B cells remain depleted. DMF treatment was associated with a significant reduction of plasma cytokines involved in inflammatory pathways, such as IL-6, IL-12, and Dectin-1 signaling. In addition, DMF lowered plasma cytokines that are dysregulated in psoriasis and involved in allograft rejection pathways. Ocrelizumab treatment led to the upregulation of neurotropic proteins in the plasma of MS patients, including proteins involved in NAD+ biosynthesis and tryptophan catabolism. Conclusion Our high-dimensional immunophenotyping results suggest that to exert their effects on MS patients, DMF and ocrelizumab both increase NK cells in addition to affecting different immune cell populations and cytokine pathways. Detecting similarities between the mechanisms of the two drugs may contribute to identifying more specific therapeutic targets." @default.
• W4308839704 created "2022-11-17" @default.
• W4308839704 creator A5025501697 @default.
• W4308839704 creator A5033220689 @default.
• W4308839704 creator A5047139976 @default.
• W4308839704 creator A5054970583 @default.
• W4308839704 creator A5055055894 @default.
• W4308839704 creator A5057339202 @default.
• W4308839704 creator A5063561778 @default.
• W4308839704 creator A5075977363 @default.
• W4308839704 creator A5081181514 @default.
• W4308839704 date "2022-11-10" @default.
• W4308839704 modified "2023-09-28" @default.
• W4308839704 title "High-dimensional immune profiling of dimethyl fumarate and ocrelizumab in multiple sclerosis" @default.
• W4308839704 cites W1521119381 @default.
• W4308839704 cites W1900528944 @default.
• W4308839704 cites W1988672411 @default.
• W4308839704 cites W2009495078 @default.
• W4308839704 cites W2010084870 @default.
• W4308839704 cites W2012815535 @default.
• W4308839704 cites W2032300322 @default.
• W4308839704 cites W2037234036 @default.
• W4308839704 cites W2044953408 @default.
• W4308839704 cites W2045279953 @default.
• W4308839704 cites W2078936538 @default.
• W4308839704 cites W2092733402 @default.
• W4308839704 cites W2096499705 @default.
• W4308839704 cites W2097813112 @default.
• W4308839704 cites W2101684276 @default.
• W4308839704 cites W2103445898 @default.
• W4308839704 cites W2115128747 @default.
• W4308839704 cites W2126336004 @default.
• W4308839704 cites W2140881278 @default.
• W4308839704 cites W2156831625 @default.
• W4308839704 cites W2158980418 @default.
• W4308839704 cites W2160872052 @default.
• W4308839704 cites W2170933182 @default.
• W4308839704 cites W2172172243 @default.
• W4308839704 cites W2205231349 @default.
• W4308839704 cites W2282530297 @default.
• W4308839704 cites W2288282768 @default.
• W4308839704 cites W2343323874 @default.
• W4308839704 cites W2345356016 @default.
• W4308839704 cites W2423259930 @default.
• W4308839704 cites W2466753021 @default.
• W4308839704 cites W2510028480 @default.
• W4308839704 cites W2565433170 @default.
• W4308839704 cites W2577405982 @default.
• W4308839704 cites W2594894796 @default.
• W4308839704 cites W2609394914 @default.
• W4308839704 cites W2618501664 @default.
• W4308839704 cites W2734067368 @default.
• W4308839704 cites W2767624851 @default.
• W4308839704 cites W2801366111 @default.
• W4308839704 cites W2805243014 @default.
• W4308839704 cites W2884787108 @default.
• W4308839704 cites W2897760136 @default.
• W4308839704 cites W2904938788 @default.
• W4308839704 cites W2908395900 @default.
• W4308839704 cites W2958503478 @default.
• W4308839704 cites W2977367243 @default.
• W4308839704 cites W3032082124 @default.
• W4308839704 cites W3097362772 @default.
• W4308839704 doi "https://doi.org/10.1101/2022.11.05.22281806" @default.
• W4308839704 hasPublicationYear "2022" @default.
• W4308839704 type Work @default.
• W4308839704 citedByCount "0" @default.
• W4308839704 crossrefType "posted-content" @default.
• W4308839704 hasAuthorship W4308839704A5025501697 @default.
• W4308839704 hasAuthorship W4308839704A5033220689 @default.
• W4308839704 hasAuthorship W4308839704A5047139976 @default.
• W4308839704 hasAuthorship W4308839704A5054970583 @default.
• W4308839704 hasAuthorship W4308839704A5055055894 @default.
• W4308839704 hasAuthorship W4308839704A5057339202 @default.
• W4308839704 hasAuthorship W4308839704A5063561778 @default.
• W4308839704 hasAuthorship W4308839704A5075977363 @default.
• W4308839704 hasAuthorship W4308839704A5081181514 @default.
• W4308839704 hasBestOaLocation W43088397041 @default.
• W4308839704 hasConcept C159654299 @default.
• W4308839704 hasConcept C196166836 @default.
• W4308839704 hasConcept C203014093 @default.
• W4308839704 hasConcept C2776819417 @default.
• W4308839704 hasConcept C2778690821 @default.
• W4308839704 hasConcept C2778843634 @default.
• W4308839704 hasConcept C2780640218 @default.
• W4308839704 hasConcept C2780653079 @default.
• W4308839704 hasConcept C502942594 @default.
• W4308839704 hasConcept C553184892 @default.
• W4308839704 hasConcept C71924100 @default.
• W4308839704 hasConcept C8891405 @default.
• W4308839704 hasConceptScore W4308839704C159654299 @default.
• W4308839704 hasConceptScore W4308839704C196166836 @default.
• W4308839704 hasConceptScore W4308839704C203014093 @default.
• W4308839704 hasConceptScore W4308839704C2776819417 @default.
• W4308839704 hasConceptScore W4308839704C2778690821 @default.
• W4308839704 hasConceptScore W4308839704C2778843634 @default.
• W4308839704 hasConceptScore W4308839704C2780640218 @default.
• W4308839704 hasConceptScore W4308839704C2780653079 @default.
• W4308839704 hasConceptScore W4308839704C502942594 @default.
• W4308839704 hasConceptScore W4308839704C553184892 @default.

• next